The ANSWER-HF trial is the first randomized, double-blind study to evaluate Angiotensin Receptor-Neprilysin Inhibition (ARNI) specifically in Chronic Chagas Cardiomyopathy (CCC).
Sacubitril-valsartan did not achieve a statistically significant improvement in Left Ventricular Ejection Fraction (LVEF) compared to enalapril over 6 months.
Significant reductions in NT-proBNP and a favorable hierarchical win ratio (1.80) suggest that sacubitril-valsartan possesses biological activity in this specific HFrEF etiology.
The trial confirms the safety and feasibility of evidence-based pharmacological interventions in a historically neglected and high-risk patient population.
